Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATIVAN vs A-POXIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.
Anxiety disorders,Short-term relief of anxiety symptoms,Status epilepticus (IV),Preanesthetic medication (IM/IV)
Anxiety disorders,Alcohol withdrawal syndrome,Seizure disorders (adjunctive),Preoperative sedation
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Terminal elimination half-life is 12-18 hours (mean 15 hours) in adults with normal renal function. Prolonged to 24-36 hours in elderly or moderate renal impairment (Cr Cl < 50 m L/min).
Hepatic via glucuronidation (UGT2B15, UGT2B7); major metabolite is lorazepam glucuronide (inactive).
Extensively metabolized in the liver via CYP2C19 (major) and CYP3A4 (minor) to inactive metabolites. CYP2C19 polymorphisms significantly affect clearance.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Renal excretion accounts for 60-70% of elimination, predominantly as unchanged drug. Biliary/fecal excretion accounts for 20-30%, with approximately 10% eliminated in feces as metabolites.
91% ± 2% bound to albumin. Binding is linear over therapeutic concentrations and not saturable.
95% bound to albumin.
1.3 ± 0.2 L/kg. Vd increases with obesity, hepatic cirrhosis, and in elderly patients, indicating extensive tissue distribution.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water with accumulation in tissues (brain, liver, kidneys).
Oral: 90% (range 80–100%) with first-pass metabolism negligible; Sublingual: ~90%; Intramuscular: 100% (absolute bioavailability).
Oral: 80-90%; Intramuscular: 95-100%; no data for other routes.
Cr Cl 10-50 m L/min: reduce dose by 50% or increase interval; Cr Cl <10 m L/min: avoid or reduce dose by 50-75% with caution.
No dosage adjustment required for mild-to-moderate renal impairment (Cr Cl >30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), maximum dose 20 mg daily.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or reduce dose by 50-75% with monitoring.
Mild impairment: no adjustment. Moderate-to-severe (Child-Pugh B/C): maximum dose 20 mg daily.
Children ≥6 months: 0.02-0.05 mg/kg/dose IV/IM (max 2 mg) for status epilepticus; PO: 0.05-0.1 mg/kg/dose (max 2 mg) 2-4 times daily.
Approved for GERD in children ≥1 year (weight-based: 0.5-1 mg/kg once daily; maximum 20 mg). Safety in infants <1 year not established.
Initiate at 0.5-1 mg orally daily in divided doses; increase slowly; max 2 mg/day. IV/IM: 0.5-1 mg initial; avoid doses >2 mg due to increased sedation risk.
No specific dose adjustment, but monitor renal function and for increased risk of Clostridium difficile infection and osteoporosis-related fractures.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve use for patients with inadequate alternatives.
Respiratory depression risk,Dependence and withdrawal syndrome,Abuse potential,Paradoxical reactions (hyperactivity, aggression),Use with caution in hepatic impairment,Elderly at increased risk for sedation and falls
Risk of dependence and withdrawal reactions; avoid abrupt discontinuation. May cause CNS depression and impair cognitive function. Use caution in hepatic impairment and geriatric patients.
Hypersensitivity to lorazepam or any benzodiazepine,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concurrent use with opioids (absolute unless alternative unavailable)
Severe hepatic impairment, acute narrow-angle glaucoma, myasthenia gravis, hypersensitivity to benzodiazepines, concurrent use with potent CYP3A4 inhibitors.
No specific food interactions. However, grapefruit juice may increase lorazepam levels (minor interaction). Avoid excessive caffeine as it may reduce sedative effects.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Avoid alcohol. Taking with food may delay absorption but does not affect total bioavailability.
First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avoid in first trimester if possible; use lowest effective dose.
First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome. Chronic use: Fetal hydantoin syndrome (craniofacial anomalies, growth deficiency, intellectual disability).
Enters breast milk; M/P ratio approximately 0.2–0.5; avoid or use with caution due to infant sedation and feeding difficulties; monitor for drowsiness and weight gain.
Excreted into breast milk; M/P ratio ~0.3-0.5. Infant serum levels may reach subtherapeutic concentrations. Risk of sedation and poor feeding. Consider risk-benefit; monitor infant for drowsiness and weight gain.
Increased clearance and volume of distribution in pregnancy may necessitate dose increase; monitor clinical response; use lowest effective dose; avoid late third trimester if possible.
Enhanced clearance (up to 50% increase) in pregnancy requires dose adjustments to maintain therapeutic levels. Frequent monitoring of free phenytoin levels recommended; total levels may be misleading due to decreased albumin. Postpartum dose reduction likely needed.
ATIVAN (lorazepam) is a benzodiazepine with intermediate onset and duration; useful for status epilepticus (IV) and preoperative anxiolysis. Monitor for respiratory depression, especially when combined with opioids. Not ideal for long-term anxiety due to tolerance and dependence risk. Use with caution in elderly (increased fall risk).
A-POXIDE is a potent benzodiazepine with rapid onset; use lowest effective dose to minimize tolerance. Monitor for respiratory depression, especially in elderly or those with COPD. Abrupt discontinuation may cause withdrawal seizures; taper gradually over weeks to months. Avoid concurrent use with other CNS depressants including alcohol.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking ATIVAN.,Take exactly as prescribed; do not increase dose or stop abruptly without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision.,Report any unusual mood changes, confusion, or respiratory difficulty.,This medication can be habit-forming; prolonged use may lead to dependence.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Do not consume alcohol while taking this medication.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Do not stop taking abruptly; follow your doctor's instructions for tapering the dose.,Inform your doctor if you have a history of substance abuse or respiratory conditions.,Store at room temperature away from moisture and heat.,Take exactly as prescribed; do not increase dose without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATIVAN vs A-POXIDE, answered by our medical review team.
ATIVAN is a Benzodiazepine that works by Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.. A-POXIDE is a Benzodiazepine that works by GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATIVAN and A-POXIDE depend on the specific clinical indication. These are both Benzodiazepine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATIVAN is: 2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.. The standard adult dose of A-POXIDE is: GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATIVAN and A-POXIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATIVAN is classified as Category C. First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avo. A-POXIDE is classified as Category C. First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonata. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.